Could Hydromethylthionine Be An Effective Alzheimer’s Treatment?

Alzheimer’s disease continues to be at the center of medical research, with breakthroughs in its source and cause helping to advise potential new treatments.  This week, one of these treatments has emerged from the Scotland- and Singapore-based TauRx.  

TauRx reported unexpected results pharmacokinetic analysis of the effective relationships between treatment dose, blood levels, and the pharmacological activity of their new drug on the brain’s of more than 1,000 patients diagnosed with mild-to-moderate Alzheimer’s disease. 

This new drug—formerly known as LMTM—is called hydromethylthionine.  

Previous Phase 3 global clinical trials of the drug showed that, even at its lowest dose (8mg per day), produced favorable concentration-dependent results on cognitive decline and brain atrophy.  

When taken as a tablet, this drug is a WHO-approved non-proprietary treatment that blocks abnormal aggregation of tau protein in the brain.  This, of course, is quickly becoming the most recognized driver of clinical dementia.  

Originally, the drug was given to nearly 1,700 patients with mild-to-moderate Alzheimer’s disease between 2012 and 2016.  The researchers tested Hydromethylthionine at doses between 150 and 250 mg per day (against the lowest possible dose of 8 mg per day).  Obviously, they were all found to be effective. 

Aberdeen University’s Professor Claude Wischik explains, “Since we already have a substantial database supporting the safety and tolerability of hydromethylthionine in clinical trials of patients with mild-to-moderate Alzheimer’s disease, the additional results of this analysis have given us the confidence to expand the scope of the new TauRx Lucidity clinical trial to confirm the potential efficacy of the hydromethylthionine 16 mg/day dose in these types of patients.”

Thus, the researchers ran this new trial of more than 1,000 patients to find positive results using the Alzheimer’s Disease Assessment Scale-cognitive subscale.  Abbreviated as ADAS-Cog, this is the industry’s standard scale for measuring the observable neuropsychological changes in Alzhiemer’s disease during clinical trials.  A change value of 4 points is, in general, considered to be clinically meaningful. 

The executive chairman of TauRx Therapeutics Ltd goes on to say, “In addition to the reduction in brain atrophy, we were surprised to see the large cognitive effects of treatment in the patient group with the higher blood levels of hydromethylthionine at the 8 mg daily dose. According to scores from the ADAS-cog scale, the effect was around 7.5 points, or three times that seen from current routine Alzheimer’s treatments, and would be equivalent to an 85 percent reduction in cognitive decline over 65 weeks.”